Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2016 17:40 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Registers Shares Underlying Existing Warrants; No Change in Fully Diluted Share Count

RUTHERFORD, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
December 07, 2016 07:53 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics

RUTHERFORD, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular...
December 05, 2016 08:14 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. Listed by Merck as a National Reference Laboratory for KEYTRUDA® (pembrolizumab) Companion Diagnostic Testing

Reinforces CGI’s Position as a Leader in Immuno-Oncology & Companion Diagnostics For PD-L1 Testing & MonitoringCompany Expects Significant Growth in Comprehensive Molecular & Immune...
December 01, 2016 09:20 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. and Leading Collaborators to Present Innovative Insights That Will Advance Precision Medicine in Diffuse Large B-cell Lymphoma (DLBCL) at American Society of Hematology (ASH) Annual Meeting 2016

The two studies presented at ASH highlight new data on genomic and immune biomarkers, as well as biological pathways of the aggressive cancer diffuse large B-cell lymphoma (DLBCL), the most common...
November 16, 2016 16:01 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. Ranked Among Fastest Growing Companies For Third Consecutive Year By Deloitte’s Technology Fast 500™ - Ranks 233 in 2016

RUTHERFORD, N.J., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
November 10, 2016 07:00 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year Revenue Growth and Highlights Path to Future Profitability

Company reports third quarter revenues of $6.8 Million, an increase of 68% over the third quarter of 2015The revenue growth rate was 58% for the first 9 months of 2016 as compared to...
November 03, 2016 07:00 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016

RUTHERFORD, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
November 02, 2016 07:00 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. Launches Focus::Renal™, a Unique, Comprehensive and Highly Sensitive Next Generation Sequencing (NGS) Panel for Enabling Precision and Personalized Medicine in Renal Cancers

Cancer Genetics, Inc. received CLIA approval for Focus::Renal™, a unique, highly sensitive and comprehensive NGS panel for renal cancer. Focus::Renal™ was developed as a result of multiple...
November 01, 2016 07:00 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. to Present Insights on Patient Stratification & Diagnostics for Immunotherapy Trials at the Companion Diagnostics (CDx) Symposium on November 2-3

The CDx market is expected to reach six billion US dollars by 2022 and drive significant cost savings by improving trial outcomes and enabling precision patient segmentation strategies.CGI will be...
October 14, 2016 16:01 ET | Source: Cancer Genetics, Inc.

Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock Conference on October 20

RUTHERFORD, N.J., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...